share_log
Reuters ·  Apr 25 16:05
Aligos Therapeutics Presents Positive Clinical Data at Escmid 2024 From the Alg-097558 Phase 1 Study
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment